CMR — Center for Molecular Research
Strontium-89
Art. N°
Hover to zoom · click to enlarge
Radionuclides
Sr-89 is among the most effective modern therapeutic agents for palliative treatment of patients with metastatic tumors in the prostate, breast, kidneys and lungs. 89Sr is also used as an alternative to (or supplement of) external beam therapy for managing pain syndrome in bone cancer.
- Grade
- Non-carrier added radionuclide; GMP product; tested for sterility and bacterial endotoxins
- Half-life
- 50.5 days
- Chemical form
- 89Strontium solution as a chloride
- Concentration
- 10.9-22.6 mg/ml
- Radioactive impurities
- 90Sr <= 2.0x10^-4%, other radionuclides <= 1.0x10^-3%, other gamma-emitting impurities <= 0.35%
- Radioactive concentration
- 33.3-40.7 MBq/ml on production date
